1. [Home](https://www.g2.com/) 2. ... 3. [Emerging AI Software](https://www.g2.com/categories/emerging-ai-software) 4. [BioSniper Discussions](https://www.g2.com/products/biosniper/discuss) [ ![Product Avatar Image](https://images.g2crowd.com/uploads/product/image/large_detail/large_detail_6ab6f70c1ab6bf3d5df02dbe57565a05/biosniper.png "Product Avatar Image") ](/products/biosniper/reviews) [ BioSniper ](/products/biosniper/reviews) 0 ratings BioSniper is an AI-native biotech thesis compiler and due diligence platform purpose-built for buy-side and sell-side equity analysts, healthcare venture capitalists, and specialized life science investors. Traditional biotech investing relies on static event calendars, manual SEC filing reviews, and disconnected spreadsheets—creating significant latency and blind spots around binary clinical readouts and regulatory action dates. BioSniper transforms this workflow: investors describe any complex medical or financial thesis in plain English, and the platform compiles it into executable screening protocols, specialist-agent audits, scoring rules, and strict evidence gates. Key capabilities include: 1. Free Biotech Catalyst Calendar: Real-time tracking of FDA action dates (PDUFA, CRLs, AdComs) and clinical trial readouts across 900+ public biotechnology companies. 2. 7-Source Evidence Verification: Automated normalization across SEC EDGAR (10-K, 10-Q, 8-K, Form 4), FDA CDER/CBER regulatory dockets, ClinicalTrials.gov, PubMed scientific literature, patent filings (USPTO/Google Patents), news wires, and real-time equity market data. 3. Citation-Enforced Diligence: Every claim, financial metric, and clinical timeline must link directly to its underlying public source document. Quoted text is verified against original records; unsubstantiated claims and LLM hallucinations are programmatically blocked from investment memos. 4. Parsed SEC Financials & Cash Runway: Instant breakdown of cash reserves, burn rates, financing overhangs, and automated runway horizon projections to evaluate dilution risk ahead of clinical milestones. 5. Spotter Research Workspace: Specialized agent framework that reads primary regulatory submissions, extracts MD&A risks, and produces defensible, fully cited due diligence reports. BioSniper offers a transparent freemium model including free access to the catalyst calendar and 200 monthly AI credits, with professional research subscriptions starting at $39/month. REGULATORY & COMPLIANCE NOTICE: BioSniper is a financial technology research and workflow automation software platform. BioSniper is NOT a registered investment adviser, broker-dealer, or financial analyst and does NOT provide personalized investment advice or buy/sell ratings. All outputs are analytical information intended solely for institutional research and due diligence. Show More When users leave BioSniper reviews, G2 also collects common questions about the day-to-day use of BioSniper. These questions are then answered by our community of 850k professionals. Submit your question below and join in on the G2 Discussion. * * * ### 0.0 Nps Score ### All BioSniper Discussions Search Most CommentedMost HelpfulCommon QuestionsNewest All DiscussionsDiscussions with CommentsCommon QuestionsDiscussions without Comments FilterFilter Filter byExpand/Collapse Sort by Most Commented Most Helpful Common Questions Newest Filter by All Discussions Discussions with Comments Common Questions Discussions without Comments Sorry... There are no questions about BioSniper yet. ## Start a New Software Discussion Have a software question? Get answers from real users and experts Start A Discussion * * * ![Product Avatar Image](https://images.g2crowd.com/uploads/product/image/thumb_square/thumb_square_6ab6f70c1ab6bf3d5df02dbe57565a05/biosniper.png "Product Avatar Image") ### Have you used BioSniper before? Answer a few questions to help the BioSniper community [ Yes ](javascript:void(0))[ Yes ](https://www.g2.com/login?context=product_review&return_to=https%3A%2F%2Fwww.g2.com%2Fproducts%2Fbiosniper%2Fdiscuss%3Fsmall_ask%3Dbiosniper) No